Vimarsana
Biggest News Aggregation in the World

Katya Ravid News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Katya Ravid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Katya Ravid Today - Breaking & Trending Today

Bone marrow cancer spotted through MRI - Vimarsana News

Bone marrow cancer spotted through MRI

Doctors can effectively identify bone marrow cancer (myelofibrosis) using Magnetic Resonance Imaging (MRI).

Source: femina.in
2022 Perkins Service Awards Go to Three Longtime BU Staffers - Vimarsana News

2022 Perkins Service Awards Go to Three Longtime BU Staffers

The recipients of the 2022 John F. Perkins Awards for Distinguished Service are BU staffers Francis Antonelli, Nancy Clinton, and Cynthia Bradford.

Source: bu.edu
BUSM receives $2.7 million grant to reduce disparities in cardio-oncology - Vimarsana News

BUSM receives $2.7 million grant to reduce disparities in cardio-oncology

BUSM receives $2.7 million grant to reduce disparities in cardio-oncology With a growing need to better understand the many links between heart disease and cancer, the two leading causes of death worldwide, the American Heart Association (AHA), the world's leading voluntary organization dedicated to a world of longer, healthier lives, announced grants focused on this area of scientific research. More than $11 million in research grants has been awarded to create the AHA's newest Strategically Focused Research Network on disparities in cardio-oncology. Boston University School of Medicine (BUS...

Pharmaxis Ltd has multiple potential value inflection points with two drugs advancing in clinical trials - Vimarsana News

Pharmaxis Ltd has multiple potential value inflection points with two drugs advancing in clinical trials

Pharmaxis Ltd (ASX:PXS) (FRA:UUD) has multiple potential value inflection points over the next two years, with two drugs in clinical trials that are due to report meaningful efficacy and safety endpoints in patients by the end of 2022.  The company has a platform technology that has delivered a pipeline of first in class or best in class clinical drugs for inflammatory and fibrotic diseases. The first of these drugs already has an IND approval from the FDA and is currently being trialled in myelofibrosis patients. Its lead asset PXS-5505 – with disease-modifying potential in myelofibrosi...